Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Look into Treatment Mechanism and Therapeutic Potential

Researchers show the transplantation protocol for mesenchymal stem cells (MSCs), discuss the potential therapeutic mechanisms, and summarize clinical trials on MSCs for treating ischemic stroke.
[Journal of Neurology]
Li, J., Zhang, Q., Wang, W., Lin, F., Wang, S., & Zhao, J. (2020). Mesenchymal stem cell therapy for ischemic stroke: A look into treatment mechanism and therapeutic potential. Journal of Neurology. https://doi.org/10.1007/s00415-020-10138-5 Cite
Abstract

Continue reading “Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Look into Treatment Mechanism and Therapeutic Potential”

Bookmark

No account yet? Register

0
Share

Cardiomyocyte Transplantation after Myocardial Infarction Alters the Immune Response in the Heart

The authors showed for the first time that the immune response is altered as a result of syngeneic neonatal cardiomyocyte transplantation after myocardial infarction leading to improved cardiac pump function as observed by magnetic resonance imaging in C57BL/6J mice.
[Cells]
Vasudevan, P., Wolfien, M., Lemcke, H., Lang, C. I., Skorska, A., Gaebel, R., Koczan, D., Lindner, T., Engelmann, R., Vollmar, B., Krause, B. J., Wolkenhauer, O., Lang, H., Steinhoff, G., & David, R. (2020). Cardiomyocyte Transplantation after Myocardial Infarction Alters the Immune Response in the Heart. Cells, 9(8), 1825. https://doi.org/10.3390/cells9081825 Cite
Full Article

Continue reading “Cardiomyocyte Transplantation after Myocardial Infarction Alters the Immune Response in the Heart”

Bookmark

No account yet? Register

0
Share

Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Scientists treated 14 relapsed or refractory diffuse large B-cell lymphoma patients by combining autologous hematopoietic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy.
[Immunotherapy]
Wang, T., Gao, L., Wang, Y., Zhu, W., Xu, L., Wang, Y., Yue, W., Tang, G., Chen, L., Chen, J., Zhang, W., Yu, X., Feng, D., & Yang, J. (2020). Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma. Immunotherapy. https://doi.org/10.2217/imt-2020-0075 Cite
Abstract

Continue reading “Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

A Lung Tropic AAV Vector Improves Survival in a Mouse Model of Surfactant B Deficiency

Scientists report a rationally designed adeno-associated virus 6 capsid that demonstrates efficiency in lung epithelial cell transduction based on imaging and flow cytometry analysis.
[Nature Communications]
Kang, M. H., van Lieshout, L. P., Xu, L., Domm, J. M., Vadivel, A., Renesme, L., Mühlfeld, C., Hurskainen, M., Mižíková, I., Pei, Y., van Vloten, J. P., Thomas, S. P., Milazzo, C., Cyr-Depauw, C., Whitsett, J. A., Nogee, L. M., Wootton, S. K., & Thébaud, B. (2020). A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency. Nature Communications, 11(1), 3929. https://doi.org/10.1038/s41467-020-17577-8 Cite
Full Article

Continue reading “A Lung Tropic AAV Vector Improves Survival in a Mouse Model of Surfactant B Deficiency”

Bookmark

No account yet? Register

0
Share

In Vivo Gene Therapy for Canine SCID-X1 Using Cocal-Pseudotyped Lentiviral Vector

Scientists developed an in vivo gene therapy approach to treat canine X-linked severe combined immunodeficiency after hematopoietic stem and progenitor cell mobilization and systemic delivery of the therapeutic vector.
[Human Gene Therapy]
Rajawat, Y. S., Humbert, O., Cook, S. M., Radtke, S., Pande, D., Enstrom, M., Wohlfahrt, M. E., & Kiem, H.-P. (2020). In vivo gene therapy for canine SCID-X1 using cocal-pseudotyped lentiviral vector. Human Gene Therapy. https://doi.org/10.1089/hum.2020.127 Cite
Abstract

Continue readingIn Vivo Gene Therapy for Canine SCID-X1 Using Cocal-Pseudotyped Lentiviral Vector”

Bookmark

No account yet? Register

0
Share

Dental Follicle Stem Cells Rescue the Regenerative Capacity of Inflamed Rat Dental Pulp through a Paracrine Pathway

Researchers focused on the paracrine effects of rat dental follicle stem cells (DFSCs) on the inflammation and regeneration of rat injured dental pulp to detect whether DFSCs are a potential candidate for mesenchymal stem cell-based minimally invasive vital pulp therapy.
[Stem Cell Research & Therapy]
Hong, H., Chen, X., Li, K., Wang, N., Li, M., Yang, B., Yu, X., & Wei, X. (2020). Dental follicle stem cells rescue the regenerative capacity of inflamed rat dental pulp through a paracrine pathway. Stem Cell Research & Therapy, 11(1), 333. https://doi.org/10.1186/s13287-020-01841-1 Cite
Full Article

Continue reading “Dental Follicle Stem Cells Rescue the Regenerative Capacity of Inflamed Rat Dental Pulp through a Paracrine Pathway”

Bookmark

No account yet? Register

0
Share

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings, Inc. announced the United States Food and Drug Administration approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinson’s disease.
[IMAC Holdings, Inc. (GlobeNewswire, Inc.) ]
Press Release

Continue reading “IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease”

Bookmark

No account yet? Register

0
Share

Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner: Personalized Stem Cells

Calidi Biotherapeutics, Inc., announced that the Investigational New Drug application submitted by its partner, Personalized Stem Cells, Inc. They have received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy.
[Calidi Biotherapeutics, Inc.]
Press Release

Continue reading “Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner: Personalized Stem Cells”

Bookmark

No account yet? Register

0
Share

Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma

The authors analyzed 60 patients with diffuse large B cell lymphoma treated with FDA-approved CD19 chimeric antigen receptor (CAR) T cells and report the incidence, risk factors, and management of infections during the first year after treatment.
[Blood Cancer Journal]
Wudhikarn, K., Palomba, M. L., Pennisi, M., Garcia-Recio, M., Flynn, J. R., Devlin, S. M., Afuye, A., Silverberg, M. L., Maloy, M. A., Shah, G. L., Scordo, M., Dahi, P. B., Sauter, C. S., Batlevi, C. L., Santomasso, B. D., Mead, E., Seo, S. K., & Perales, M.-A. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 10(8), 1–11. https://doi.org/10.1038/s41408-020-00346-7 Cite
Full Article

Continue reading “Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

Twitter Account of Embattled #MeTooSTEM Founder Suspended

Twitter has suspended the account of MeTooSTEM founder BethAnn McLaughlin after allegations emerged that the former Vanderbilt University neuroscientist fabricated the Twitter account of an apparently nonexistent female Native American anthropologist at Arizona State University who had claimed to be an anonymous victim of sexual harassment by a Harvard professor.
[ScienceInsider]
Press Release

Continue reading “Twitter Account of Embattled #MeTooSTEM Founder Suspended”

Bookmark

No account yet? Register

0
Share

Metabolic Conditioning of CD8+ Effector T Cells for Adoptive Cell Therapy

Investigators showed that transient glucose restriction in activated CD8+ effector T cells metabolically primed effector functions and enhanced tumor clearance in mice.
[Nature Metabolism]
Klein Geltink, R. I., Edwards-Hicks, J., Apostolova, P., O’Sullivan, D., Sanin, D. E., Patterson, A. E., Puleston, D. J., Ligthart, N. A. M., Buescher, J. M., Grzes, K. M., Kabat, A. M., Stanczak, M., Curtis, J. D., Hässler, F., Uhl, F. M., Fabri, M., Zeiser, R., Pearce, E. J., & Pearce, E. L. (2020). Metabolic conditioning of CD8 + effector T cells for adoptive cell therapy. Nature Metabolism, 1–14. https://doi.org/10.1038/s42255-020-0256-z Cite
Abstract

Continue reading “Metabolic Conditioning of CD8+ Effector T Cells for Adoptive Cell Therapy”

Bookmark

No account yet? Register

0
Share

Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma

Targeting melanosomal proteins or oncogenic CDK4R24C by adoptive cell transfer of the same epitope-specific CD8+ T cells revealed diverse genetic and non-genetic immune escape mechanisms.
[Immunity]
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M., Bawden, E., Hinze, D., Boorn-Konijnenberg, D. van den, Daoud, M., Aymans, P., Landsberg, J., Smyth, M. J., Flatz, L., Tüting, T., Bald, T., Gebhardt, T., & Hölzel, M. (2020). Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity, 0(0). https://doi.org/10.1016/j.immuni.2020.07.007 Cite
AbstractGraphical Abstract

Continue reading “Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma”

Bookmark

No account yet? Register

0
Share
Share